Entera Bio Ltd. secured approximately $275 million through an oversubscribed private placement led by existing investor BVF Partners L.P. The funds will extend the company's cash runway into 2030 and fully support Phase 3 clinical trials for EB613, an oral peptide tablet for osteoporosis treatment. The proceeds will also advance development of EB612 for hypoparathyroidism and support general corporate purposes. The private placement is expected to close by July 28, 2026, with BVF gaining rights to designate two board members.
Guangzhou's Nansha District is rapidly advancing as a global cross-border trade hub with its state-of-the-art automated container terminal and integrated multimodal transport system. In 2025, Nansha Port handled over 22.6 million TEUs and operates 18...
Nord Precious Metals Mining Inc., focused on high-grade silver mining in Northern Ontario, announced that CEO Frank J. Basa will present live at the OTCQB Virtual Investor Conference on August 5, 2026. The event allows investors to engage directly wi...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, effective August 6, 2026. Distribution rates vary widely across ETFs, reflecting different investment strategies and associated risks, including semiconductor, AI, crypto, metals, an...
The global military drone market is expected to grow from $16.5 billion in 2025 to $42.8 billion by 2035, at a CAGR of 10%. Growth is fueled by AI-powered autonomous systems, defense modernization, and rising demand for surveillance, electronic warfa...
Man Group PLC has disclosed a 1.66% interest in Senior Plc's ordinary shares, totaling 6,962,764 shares, held through cash-settled derivatives as of August 3, 2026. The stake was increased by 104,804 shares via an equity swap transaction priced at ap...
